SEARCH

SEARCH BY CITATION

References

  • 1
    Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet 1999; 353: 12537.
  • 2
    Lee WM. Hepatitis B virus infection. N. Engl. J. Med. 1997; 337: 173345.
  • 3
    Di Bisceglie AM. Hepatitis C (see comments). Lancet 1998; 351: 3515.
  • 4
    Kew MC, Yu MC, Kedda M-A, Coppin A, Sarkin A, Hodkinson J. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 1997; 112: 1847.
  • 5
    Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 1998; 75: 34754.
  • 6
    Okuda K. Hepatocellular carcinomas associated with hepatitis B and C virus infections: Are they any different? Hepatology 1995; 22: 18835.
  • 7
    Lauer GM, Walker BD. Hepatitis C virus infection. N. Engl. J. Med. 2001; 345: 4152.
  • 8
    Di Bisceglie AM. Natural history of hepatitis C: Its impact on clinical management. Hepatology 2000; 31: 101418.
  • 9
    Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann. Intern. Med. 2000; 132: 296305.
  • 10
    Blum HE. Variants of hepatitis B, C and D viruses: Molecular biology and clinical significance. Digestion 1995; 56: 8595.
  • 11
    Thursz MR, Kwiatkowski D, Allsopp CE, Greenwood BM, Thomas HC, Hill AV. Association between an MHC class II allele and clearance of hepatitis B virus in the Gambia. N. Engl. J. Med. 1995; 332: 10659.
  • 12
    Congia M, Clemente MG, Dessi C et al. HLA class II genes in chronic hepatitis C virus-infection and associated immunological disorders. Hepatology 1996; 24: 133841.
  • 13
    Tibbs C, Donaldson P, Underhill J, Thomson L, Manabe K, Williams R. Evidence that the HLA DQA1*03 allele confers protection from chronic HCV-infection in northern European caucasoids. Hepatology 1996; 24: 13425.
  • 14
    Kuzushita N, Hayashi N, Moribe T et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998; 27: 2404.
  • 15
    Donato F, Tagger A, Chiesa R et al. Hepatitis B and C virus infection, alcohol drinking and hepatocellular carcinoma: A case-control study in Italy. Hepatology 1997; 26: 57984.
  • 16
    Eaton DL, Gallagher EP. Mechanism of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol. 1994; 34: 13572.
  • 17
    Chen C-J, Wang L-Y, Lu S-N et al. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 1996; 24: 3842.
  • 18
    Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G to T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl Acad. Sci. USA 1993; 90: 858690.
  • 19
    Bailey EA, Iyer RS, Stone MP, Harris TM, Essigmann JM. Mutational properties of the primary aflatoxin B1-DNA adduct. Proc. Natl Acad. Sci. USA 1996; 93: 15359.
  • 20
    Mandishona E, MacPhail AP, Gordeux VR et al. Dietary iron overload as a risk factor for hepatocellular carcinoma in black Africans. Hepatology 1998; 27: 15636.
  • 21
    Mant JWF, Vessey MP. Trends in mortality from primary liver cancer in England and Wales. Br. J. Cancer 1995; 72: 8003.
  • 22
    Waetjen LE, Grimes DA. Oral contraceptives and primary liver cancer: Temporal trends in 3 countries. Obstet. Gynecol. 1996; 88: 9459.
  • 23
    Poynard T, Bedossa P, Opolon P et al. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 82532.
  • 24
    Deuffic S, Poynard T, Buffat L, Valleron A-J. Trends in primary liver cancer. Lancet 1998; 351: 21415.
  • 25
    Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979–94. Lancet 1997; 350: 11423.
  • 26
    De Vos Irvine H, Goldberg D, Hole DJ, McMenamin J. Trends in primary liver cancer. Lancet 1998; 351: 21516.
  • 27
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 1999; 340: 74550.
  • 28
    Yuen MF, Cheng CC, Lauder IJ, Lam SK, Ooi CG, Lai CL. Early detection of hepatocellular carcinoma increases the chance of treatment: Hong Kong experience. Hepatology 2000; 31: 3305.
  • 29
    Villa E, Moles A, Ferretti I et al. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32: 2338.
  • 30
    El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 625.
  • 31
    Cho KJ, Lee SS, Khang SK. Histiocytic necrotizing lymphadenitis. A clinico-pathologic study of 45 cases with in situ hybridization for Epstein–Barr virus and hepatitis B virus. J. Korean Med. Sci. 1996; 11: 40914.
  • 32
    Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet 1981; 2: 112933.
  • 33
    Chang MH, Chen CJ, Lai MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group (see comments). N. Engl. J. Med. 1997; 336: 18559.
  • 34
    Nakamoto Y, Guidotti L, Kuhlen C, Fowler P, Chisari F. Immune pathogenesis of hepatocellular carcinoma. J. Exp. Med. 1998; 188: 34150.
  • 35
    Matsubara K, Tokino T. Integration of hepatitis B virus DNA and its implications for hepatocarcinogenesis. Mol. Biol. Med. 1990; 7: 24360.
  • 36
    Buendia MA. Hepatitis B viruses and hepatocellular carcinoma. Adv. Cancer Res. 1992; 59: 167226.
  • 37
    Dejean A, De The H. Hepatitis B virus as an insertional mutagene in a human hepatocellular carcinoma. Mol. Biol. Med. 1990; 7: 21322.
  • 38
    Adachi S, Okuno M, Matsushima-Nishiwaki R et al. Phosphorylation of retinoid X receptor suppresses its ubiquitination in human hepatocellular carcinoma. Hepatology 2002; 35: 33240.
  • 39
    Wang C, Siddiqui A. Structure and function of the hepatitis C virus internal ribosome entry site. Curr. Top. Microbiol. Immunol. 1995; 203: 99115.
  • 40
    Caselmann WH. Trans-activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Adv. VirusRes. 1996; 47: 253302.
  • 41
    Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc. Natl Acad. Sci. USA 1994; 91: 10 3504.
  • 42
    Hohne M, Schaefer S, Seifer M, Feitelson MA, Paul D, Gerlich WH. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J. 1990; 9: 113745.
  • 43
    Koike K, Moriya K, Iino S et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19: 81019.
  • 44
    Benn J, Schneider RJ. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc. Natl Acad. Sci. USA 1995; 92: 11 21519.
  • 45
    Becker S, Lee T-H, Butel J, Slagle B. Hepatitis B virus X protein interferes with cellular DNA repair. J. Virol. 1998; 72: 26672.
  • 46
    Su F, Schneider R. Hepatitis B virus HBx protein sensitizes cells to apoptotic killing by tumor necrosis factor alpha. Proc. Natl Acad. Sci. USA 1997; 94: 87449.
  • 47
    Terradillos O, Pollicino T, Lecoeur H et al. p53-independent apoptotic effects of the hepatitis B virus HBx protein in vivo and in vitro. Oncogene 1998; 17: 211523.
  • 48
    Bouchard MJ, Wang LH, Schneider RJ. Calcium signaling by HBx protein in hepatitis B virus DNA replication. Science 2001; 294: 23768.
  • 49
    Ganem D. Virology. The X files: One step closer to closure. Science 2001; 294: 2299300.
  • 50
    Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351: 31720.
  • 51
    Lee HS, Kim ST, Kim CY. Identification of integrated hepatitis B virus DNA sequences in human hepatocel-lular carcinomas in Korea. J. Korean Med. Sci. 1990; 5: 1458.
  • 52
    Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8: 110917.
  • 53
    Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl Acad. Sci. USA 1994; 91: 22304.
  • 54
    Ueda H, Ullrich SJ, Gangemi JD et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet. 1995; 9: 417.
  • 55
    Puisieux A, Ji J, Guillot C et al. p53-mediated cellular response to DNA damage in cells with replicative hepa-titis B virus. Proc. Natl Acad. Sci. USA 1995; 92: 13426.
  • 56
    Tennant BC. Hepatocarcinogenesis in experimental woodchuck hepatitis virus infection. In: Sirica AE, ed. The Role of Cell Types in Hepatocarcinogenesis. Boca Raton, FL: CRC Press, 1992; 32349.
  • 57
    Gerin JL. Antiviral agents for hepatitis B (editorial). Hepatology 1991; 14: 1989.
  • 58
    Korba BE, Cote PJ, Wells FV et al. Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: Molecular virologic features of the liver and lymphoid tissues. J. Virol. 1989; 63: 136070.
  • 59
    Wands JR, Liang TJ, Blum HE, Shafritz DA. Molecular pathogenesis of liver disease during persistent hepatitis B virus infection. Semin. Liver Dis. 1992; 12: 25264.
  • 60
    Etiemble J, Degott C, Renard CA et al. Liver-specific expression and high oncogenic efficiency of a c-myc transgene activated by woodchuck hepatitis virus insertion. Oncogene 1994; 9: 72737.
  • 61
    Wang H-P, Zhang L, Dandri M, Rogler C. Antisense downregulation of N-myc1 in woodchuck hepatoma cells reverses the malignant phenotype. J. Virol. 1998; 72: 21928.
  • 62
    Bannasch P, Khoshkhou NI, Hacker HJ et al. Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res. 1995; 55: 331830.
  • 63
    Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 35962.
  • 64
    Kuo G, Choo QL, Alter HJ et al. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. Science 1989; 244: 3624.
  • 65
    Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM, Rice CM. Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 1997; 277: 5704.
  • 66
    Yanagi M, Purcell RH, Emerson SU, Bukh J. Transcripts from a single full-length cDNA clone of hepatitis C virus are infectious when directly transfected into the liver of a chimpanzee. Proc. Natl Acad. Sci. USA 1997; 94: 873843.
  • 67
    Zeuzem S, Franke A, Lee J-H, Herrman GR, Rüster B, Roth WK. Phylogenetic analysis of hepatitis C virus isolates and their correlation to viremia, liver function tests, and histology. Hepatology 1996; 24: 10039.
  • 68
    Neumann A, Lam N, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral eficacy of interferon-alpha therapy. Science 1998; 282: 1037.
  • 69
    Bukh J, Miller RH, Purcell RH. Genetic heterogeneity of hepatitis C virus: Quasispecies and genotypes. Semin. Liver Dis. 1995; 15: 4163.
  • 70
    Simmonds P. Variability of hepatitis C virus genome. Curr. Stud. Hematol. Blood Transfus. 1994; 61: 1235.
  • 71
    Lerat H, Berby F, Trabaud M-A, Vidalin O, Major M, Trépo C. Specific detection of hepatitis C virus minus strand RNA in hematopoietic cells. J. Clin. Invest. 1996; 97: 84551.
  • 72
    Cerny A, Ferrari C, Chisari FV. The class I-restricted cytotoxic T lymphocyte response to predetermined epitopes in the hepatitis B and C viruses. Curr. Top. Microbiol. Immunol. 1994; 189: 16986.
  • 73
    Ferrari C, Valli A, Galati L et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 28695.
  • 74
    Blum HE. Does hepatitis C virus cause hepatocellular carcinoma? Hepatology 1994; 19: 2515.
  • 75
    Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Semin. Liver Dis. 1995; 15: 649.
  • 76
    Kiyosawa K, Tanaka E, Sodeyama T et al. Transition of antibody to hepatitis C virus from chronic hepatitis to hepatocellular carcinoma. Jpn J. Cancer Res. 1990; 81: 108991.
  • 77
    De Mitri MS, Poussin K, Baccarini P et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345: 41315.
  • 78
    Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J. Virol. 1995; 69: 38936.
  • 79
    Ray R., Lagging L, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. J. Virol. 1996; 70: 443843.
  • 80
    Ruggieri A, Harada T, Matsuura Y, Miyamura T. Sensitization to Fas-mediated apoptosis by hepatitis C virus core protein. Virology 1997; 229: 6876.
  • 81
    Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J. Biol. Chem. 1997; 272: 10 9836.
  • 82
    Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat. Med. 1998; 4: 10657.
  • 83
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 75967.
  • 84
    Liu B, Nicolaides NC, Markowitz S et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat. Genet. 1995; 9: 4855.
  • 85
    Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 15970.
  • 86
    Fearon ER. Human cancer syndromes: Clues to the origin and nature of cancer. Science 1997; 278: 104350.
  • 87
    Kinzler KW, Vogelstein B. Gatekeepers and caretakers. Nature 1997; 386: 7613.
  • 88
    Moradpour D, Wands JR. The molecular pathogenesis of hepatocellular carcinoma. J. Viral Hepatol. 1994; 1: 1731.
  • 89
    Moradpour D, Wands JR, Blum HE. Molecular biology of hepatitis B and C virus and hepatocellular carcinoma. Mol. Cancer Biol. 1996; 3: 875904.
  • 90
    Ozturk M. Genetic aspects of hepatocellular carcinogenesis. Semin. Liver Dis. 1999; 19: 23542.
  • 91
    Miyasaka Y, Enomoto N, Nagayama K et al. Analysis of differentially expressed genes in human hepatocellular carcinoma using suppression subtractive hybridization. Br. J. Cancer 2001; 85: 22834.
  • 92
    Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001; 33: 83240.
  • 93
    Graveel CR, Jatkoe T, Madore SJ, Holt AL, Farnham PJ. Expression profiling and identification of novel genes in hepatocellular carcinomas. Oncogene 2001; 20: 270412.